World Markets

U.S. FDA approves Alexion Pharma's blood disorder drug

Dec 21 Reuters - The U.S. Food and Drug Administration has approved Alexion Pharmaceuticals Inc's blood disorder drug Ultomiris, the pharma regulator's website on Friday.

The drug aims to treat paroxysmal nocturnal hemoglobinuria (PNH), a rare, acquired, life-threatening disorder in which red blood cells divide prematurely.

OCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">

Dec 21 Reuters - The U.S. Food and Drug Administration has approved Alexion Pharmaceuticals Inc's blood disorder drug Ultomiris, the pharma regulator's website on Friday.

The drug aims to treat paroxysmal nocturnal hemoglobinuria (PNH), a rare, acquired, life-threatening disorder in which red blood cells divide prematurely.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ALXN

Other Topics

Stocks Economy Technology

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More